Abstract: The present invention provides for methods for detection, diagnosis and prognosis of beryllium-induced disease. In one embodiment, the methods include exposing immune cells from subjects suspected of having beryllium-induced disease to beryllium and assessing the Th-1 cytokines produced. Other embodiments include the use of exposing immune cells from subjects suspected of having beryllium-induced disease to beryllium and assessing Th-1 cytokines produced and using these assessments to indicate the stage of progression of the disease. Therapeutic methods involve assessing the onset or progression of beryllium-induced disease before during and after exposure to a treatment for the disease.

Abstract: The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition. These involve the administration of anti-TSST-1 agents which are not gamma globulin.

Abstract: The invention relates to screening of patients to determine the possible presence of Kawasaki Disease. The screening involves assaying for levels of V.beta.2 or V.beta.8.1 by immunoassay, or for the mRNA expressing either of these V.beta. elements. The polymerase chain reaction is one way the mRNA level can be determined. Once the levels in the patient are determined, they are compared to normal levels. An increase is indicative of possible Kawasaki Disease.